ADVANCED BREAST CANCER

This study is testing the safety and effectiveness of a two-drug combination (alpelisib and fulvestrant) for Japanese men and postmenopausal women with a specific type of advanced breast cancer. The cancer must have a PIK3CA mutation and have worsened after standard hormone thera…

This study is testing a new drug, MEN1611, given alone and with a chemotherapy called eribulin, for people with advanced breast cancer that has specific genetic changes. The goal is to see if these treatments can help control the cancer and are safe. It is for patients whose canc…

This study is testing a new oral medicine called ARV-471 against the standard injection treatment, fulvestrant, for people with advanced breast cancer that has worsened despite prior hormone-based therapy. It involves about 624 participants who will be randomly assigned to receiv…

This study is for people with advanced HER2+ breast cancer whose cancer has spread to the brain but is stable elsewhere. It tests if adding the drug tucatinib to their current standard treatment can help keep the brain tumors from growing back longer. About 48 participants will r…

This study is testing whether adding a new oral drug, Debio 0123, to an existing cancer drug, sacituzumab govitecan, is safe and can help control advanced breast cancer. It is for people whose cancer has worsened after one or two prior treatments. The goal is to see if this combi…

This early-stage trial is testing an experimental radioactive drug called RYZ101 for people with advanced ER+ breast cancer that has spread and stopped responding to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors in patients whose ca…

This study is for people with advanced HER2-positive breast cancer that has a specific gene change called PIK3CA and has worsened after previous treatments. It aims to see if a combination of targeted drugs (trastuzumab with alpelisib, plus fulvestrant for some) can control the c…

This study is testing whether combining two existing drugs, sacituzumab govitecan and bevacizumab, can help control advanced triple-negative breast cancer that has spread. It is for people whose cancer has worsened after at least one prior treatment. The main goals are to see if …

This small pilot study is testing whether a trained, non-medical support coordinator can help women with advanced breast cancer have better conversations about their values and goals with their doctors. The coordinator meets with patients to discuss their concerns and priorities,…

This study is not testing a new treatment. Instead, researchers are using existing health records from thousands of breast cancer patients to see if real-world data can reliably answer the same questions as traditional clinical trials. They're recreating a completed trial that te…

This study aims to understand why some advanced breast cancers become resistant to the drug palbociclib. Researchers will follow 25 women with hormone-positive breast cancer, collecting tumor samples and breath/body fluid samples before treatment and when the cancer progresses. B…